Advanced Oncotherapy PLC Technological milestones update (7433H)
12 June 2017 - 4:00PM
UK Regulatory
TIDMAVO
RNS Number : 7433H
Advanced Oncotherapy PLC
12 June 2017
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Technological milestones update
Advanced Oncotherapy (AIM: AVO), the developer of
next-generation proton therapy systems for cancer treatment,
announces further notable progress in the manufacture of its first
LIGHT system.
Patient Positioning System
Multiple components of the treatment room have been
manufactured, inspected and tested by the Company's partner P-Cure
Ltd. ("P-Cure"), ahead of their integration to form a complete
patient treatment system.
The patient positioning subsystem, which includes the patient
treatment chair and robotic arm which moves the chair and patient,
is complete and has been designed to leverage LIGHT's
next-generation features. As other subsystems are completed, such
as imaging and treatment management software, they will be
integrated to form the whole Patient Positioning System, which
remains on track to be fully developed by the end of 2017.
Beam firing through RFQ
As indicated in the Investor presentation and update of 6 March
2017, the proton beam was fired through the Radio Frequency
Quadrupole ("RFQ"), at its maximum expected energy, in February
2017. Subsequent work has focused on enhancing the proton source
that feeds the RFQ; repeatability of beam firing, intensive usage
to facilitate high patient throughput and maximising safety
controls are all key elements of LIGHT.
Ionisation chamber
In addition, the Company announces it has received delivery of
the LIGHT system's ionisation chamber, from its partner Pyramid
Technical Consultants Inc., to its Geneva testing facility. The
ionisation chamber is a critical element of the LIGHT system's
overall safety system, monitoring beam position, spot size and
dosage and is situated at the delivery end of the system after the
main accelerating modules.
The novel design of the chamber is matched to the unique
properties of LIGHT and performs a precise measurement of the
position (in horizontal and vertical axes) of the proton beam, with
respect to its desired location, and is a critical element of the
LIGHT system's Patient Treatment System. It also accurately
monitors the dose (number of protons) delivered to the target. The
properties of the LIGHT ionisation chamber allow these measurements
to be taken, on a pulse by pulse basis, ensuring accuracy and
safety throughout treatment, to a level that cannot be matched by
older proton therapy technologies.
Commenting, Nicolas Serandour, CEO of Advanced Oncotherapy,
said: "As I outlined in my update to shareholders in March, the
Company remains focused on delivering the technical development of
our first LIGHT machine and its ultimate installation at Harley
Street, and I am very pleased with the progress we are making.
"We will continue to update the market with newsflow on the
integration of the LIGHT system's components, with developments on
the CCL units, addition of the SCDTLs to the RFQ and on the Patient
Positioning System anticipated in the coming weeks and months."
Advanced Oncotherapy Plc www.avoplc.com
Dr. Michael Sinclair, Tel: +44 20 3617 8728
Executive Chairman
Nicolas Serandour, CEO
Stockdale Securities (Nomad
& Joint Broker)
Antonio Bossi / David Tel: +44 20 7601 6100
Coaten
Stifel Nicolaus Europe
(Joint Broker)
Jonathan Senior / Ben Tel: +44 20 7710 7600
Maddison
Walbrook PR (Financial Tel: +44 20 7933 8780 or
PR & IR) avo@walbrookpr.com
Paul McManus / Anna Dunphy Mob: +44 7980 541 893 /
Mob: +44 7876 741 001
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy with
protons that harnesses the best in modern technology. Advanced
Oncotherapy's team "ADAM", based in Geneva, focuses on the
development of a proprietary proton accelerator called Linac Image
Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the
energy levels achieved in legacy machines but in a unit that is a
quarter of the size and between a quarter and a fifth of the cost.
This compact configuration delivers proton beams in a way that
facilitates greater precision and electronic control which is not
achievable with older technologies.
Advanced Oncotherapy will offer healthcare providers affordable
systems that will enable them to treat cancer with an innovative
technology as well as better health outcomes and lower treatment
related side effects.
Advanced Oncotherapy continually monitors the market for any
emerging improvements in delivering proton therapy and actively
seeks working relationships with providers of these innovative
technologies. Through these relationships, the Company will remain
the prime provider of an innovative and cost-effective system for
particle therapy with protons.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUAAARBKANAUR
(END) Dow Jones Newswires
June 12, 2017 02:00 ET (06:00 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Apr 2024 to May 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From May 2023 to May 2024